The Scottish Medicines Consortium published advice on seven medicines on 10 August 2026. All seven were accepted: Blueteq comment:. Almost all would typically sit on Blueteq prior-approval forms in England, several under the Cancer Drugs Fund. The breadth of disease areas in a single month’s SMC decisions illustrates the scale of the managed medicines governance challenge without a digital prior-approval system.
SMC Decisions — 13 July 2026 The Scottish Medicines Consortium published advice on six medicines on 13 July 2026. Five, which appear to be high cost drugs, were accepted. (Fezolinetant list price in the UK has not been confirmed publicly, but comparable products in the US cost approximately $10,000–15,000 per year. It is accepted within […]
The Scottish Medicines Consortium published advice on seven medicines on 8 June 2026: Blueteq comment: June SMC announcements make a substantial addition to NHS Scotland’s managed medicines portfolio. References 1. Media release: SMC decisions June 2026. Healthcare Improvement Scotland. 8 June 2026. https://www.healthcareimprovementscotland.scot/publications/media-release-smc-decisions-june-2026/ 2. Scotland Backs Bispecific Antibody for Refractory Myeloma. Medscape. 10 June 2026. […]
Unit A5, Endeavour Business Park
Penner Road, Havant
PO9 1QN
Company Registration Number: 5334133
Company VAT Number: 855 7246 95
© 2026 Blueteq Ltd
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.